Tirzepatide reduced the primary composite outcome of acute myocardial infarction, ischemic stroke, and all-cause mortality by 40% (HR 0.60) compared to GLP-1 receptor agonists in patients with type 2 diabetes and pre-existing ischemic heart disease.
Observational (n=47,719)
Yes
Does tirzepatide reduce the composite of acute myocardial infarction, ischemic stroke, and all-cause mortality compared to GLP-1RA in adults with overweight/obesity, T2DM, and pre-existing IHD?
In a real-world cohort of adults with T2DM, overweight/obesity, and pre-existing IHD, tirzepatide was associated with a significantly lower risk of major adverse cardiovascular events compared to GLP-1RAs.
Effect estimate: HR 0.60 (95% CI 0.43-0.84)
Absolute Event Rate: 7.2% vs 12%
p-value: p=0.003
BACKGROUND: While cardiovascular benefits of tirzepatide, a glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes mellitus (T2DM), and its comparative effectiveness vs glucagon-like peptide-1 receptor agonists (GLP-1RAs) is studied in randomized controlled trials, real-world outcomes may provide critical insights. OBJECTIVES: The purpose of this study was to examine the cardiovascular benefits of tirzepatide vs GLP-1RA in people living with overweight or obesity, with T2DM, age ≥40 years, and pre-existing ischemic heart disease (IHD). METHODS: receiving either tirzepatide or GLP-1RA were identified and divided into 2 groups (tirzepatide vs GLP-1RA). After propensity score matching, Cox-proportional HRs were used to compare efficacy and safety outcomes during 1-year follow-up. RESULTS: Among 47,719 adults, 753 received tirzepatide, and 46,966 were on GLP-1RA. After propensity score matching, each group had 751 adults (mean age 59.9 ± 8.9 years, 46.5% females, 74.8% White adults in the tirzepatide group). Treatment with tirzepatide was associated with lower primary composite outcomes of acute myocardial infarction, ischemic stroke, and all-cause mortality (HR: 0.60, 95% CI: 0.43-0.84, P < 0.001). Individually, acute myocardial infarction (HR: 0.59, 95% CI: 0.38-0.91) and all-cause mortality (HR: 0.35, 95% CI: 0.14-0.88, P = 0.001) were also found to be favorable in the tirzepatide group. CONCLUSIONS: , and pre-existing IHD.
Dani et al. (Thu,) conducted a observational in Type 2 diabetes mellitus with overweight/obesity and pre-existing ischemic heart disease (n=47,719). Tirzepatide vs. Glucagon-like peptide-1 receptor agonists (GLP-1RA) was evaluated on Composite of acute myocardial infarction, ischemic stroke, and all-cause mortality (HR 0.60, 95% CI 0.43-0.84, p=0.003). Tirzepatide reduced the primary composite outcome of acute myocardial infarction, ischemic stroke, and all-cause mortality by 40% (HR 0.60) compared to GLP-1 receptor agonists in patients with type 2 diabetes and pre-existing ischemic heart disease.